New Brunswick developer Omar Boraie is funding scientific progress with a $1.5 million pledge toward research in precision medicine. In a report by Patch.com, the Omar Boraie Chair in Genomic Science provides for research in a relatively new field, that of analyzing and treating tumors at a genetic level. Developed under the auspices of Rutgers Cancer Institute of New Jersey, the chair will explore the application of highly customized therapies for patients with limited treatment options.
Boraie hopes for precision medicine to be applied to all cancer patients. Rutgers Cancer Institute Director Robert S. DiPaola, MD expressed gratitude and optimism toward the success of Boraie’s goal. President Obama emphasized the same belief in his 2015 State of the Union address when announcing the new Precision Medicine Initiative.
Shridar Ganesan, MD, Ph.D., has been named to the Omar Boraie Chair and comes uniquely qualified to lead the work. Doctor Ganesan is a highly regarded medical oncologist and academic researcher. He is the associate director for transitional science, associate professor of medicine and pharmacology at Rutgers Robert Wood Johnson Medical School, and leader of the precision medicine clinical trial at Rutgers.
According to Ganesan cancer is not one but many diseases, each with its own unique features. Rather than lumping each cancer into categories based on location in the body, he views genomic analysis as a means to exactly tailor treatment individually. Along with Mr. Boraie, Dr. Ganesan hopes to discover new understanding that will benefit even the most challenging cases.
Rutgers Cancer Institute of New Jersey is a leader in research, prevention, and treatment of cancer. The National Cancer Institute has designated Rutgers a Comprehensive Cancer Center, the first and only one in in the state. Research carried out by Rutgers is geared toward the practical application of discoveries into clinical applications.
This article was originally published through NewsWise, and can be read in full at this link.
See Omar Borie’s bio on crunchbase.com.